Fig. 3From: Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trialKaplan-Meier survival curves of progression-free survival (PFS) (A) and overall survival (OS) (B) in full analysis set of the 30 patientsBack to article page